Literature DB >> 17314526

Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection.

Andrea A Howard1, Yungtai Lo, Michelle Floris-Moore, Robert S Klein, Norman Fleischer, Ellie E Schoenbaum.   

Abstract

OBJECTIVES: To determine the associations of hepatitis C virus (HCV) infection with insulin resistance and abnormal glucose tolerance in a cohort of older adults with or at risk of HIV infection.
DESIGN: A cross-sectional study of 267 HIV-infected and 179 at-risk-uninfected adults without a history of diabetes mellitus.
METHODS: HCV antibody assays and RNA levels were performed to assess HCV status. Antiretroviral use, family history of diabetes, sedentary behavior, and sociodemographic data were obtained using standardized interviews. Fasting insulin levels and oral glucose tolerance tests were performed to assess two outcomes, the homeostasis model assessment of insulin resistance and abnormal glucose tolerance [impaired glucose tolerance (IGT) or diabetes].
RESULTS: Of 446 participants, 265 (59%) were HCV seropositive; of these, 199 (75%) had detectable HCV-RNA levels. Insulin resistance was greater among HCV-seropositive compared with seronegative participants, adjusting for body mass index, Hispanic ethnicity, age greater than 55 years, sedentary behavior (watching television > 4 h/day), HIV status, HAART, and protease inhibitor (PI) use. Ninety-eight participants (22%) had abnormal glucose tolerance (69 with IGT and 29 with diabetes). Among HIV-infected participants, 25% were on non-PI HAART and 52% were on PI HAART, but HAART and PI use were not associated with insulin resistance or abnormal glucose tolerance. Among obese participants, abnormal glucose tolerance was more common in HCV-seropositive than seronegative individuals, whereas among non-obese participants there was no association.
CONCLUSION: The potential impact of HCV co-infection and obesity on glucose metabolism should be recognized in clinical care, and addressed in future research studies of HIV-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314526      PMCID: PMC2423380          DOI: 10.1097/QAD.0b013e3280464db7

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  47 in total

1.  Screening for type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association.

Authors:  Hilla Knobler; Taiba Zhornicky; Alex Sandler; Nurit Haran; Yafa Ashur; Ami Schattner
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

3.  Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

Authors:  Jason M Hui; Archana Sud; Geoffrey C Farrell; Priyanka Bandara; Karen Byth; James G Kench; Geoffrey W McCaughan; Jacob George
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

4.  Insulin resistance/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection.

Authors:  Masanori Furutani; Toshiaki Nakashima; Yoshio Sumida; Akihisa Hirohama; Takaharu Yoh; Yuko Kakisaka; Hironori Mitsuyoshi; Hiroshi Senmaru; Takeshi Okanoue
Journal:  Liver Int       Date:  2003-08       Impact factor: 5.828

5.  Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort.

Authors:  Clara Y Jones; Joseph W Hogan; Brad Snyder; Robert S Klein; Anne Rompalo; Paula Schuman; Charles C Carpenter
Journal:  Clin Infect Dis       Date:  2003       Impact factor: 9.079

6.  Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users.

Authors:  Andrea A Howard; Robert S Klein; Ellie E Schoenbaum
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

7.  Hepatitis C virus infection and incident type 2 diabetes.

Authors:  Shruti H Mehta; Frederick L Brancati; Steffanie A Strathdee; James S Pankow; Dale Netski; Josef Coresh; Moyses Szklo; David L Thomas
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

8.  Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.

Authors:  Serhat Aytug; David Reich; Lawrence E Sapiro; David Bernstein; Najma Begum
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

9.  The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Authors:  Shruti H Mehta; Richard D Moore; David L Thomas; Richard E Chaisson; Mark S Sulkowski
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

10.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.

Authors:  Yoshizumi Shintani; Hajime Fujie; Hideyuki Miyoshi; Takeya Tsutsumi; Kazuhisa Tsukamoto; Satoshi Kimura; Kyoji Moriya; Kazuhiko Koike
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  9 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Incident hyperglycaemia among older adults with or at-risk for HIV infection.

Authors:  Sarit Polsky; Michelle Floris-Moore; Ellie E Schoenbaum; Robert S Klein; Julia H Arnsten; Andrea A Howard
Journal:  Antivir Ther       Date:  2011

3.  The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study.

Authors:  Andrea A Howard; Donald R Hoover; Kathryn Anastos; Xi Wu; Qiuhu Shi; Howard D Strickler; Stephen R Cole; Mardge H Cohen; Andrea Kovacs; Michael Augenbraun; Patricia S Latham; Phyllis C Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

4.  Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.

Authors:  Kristen M Marks; Douglas Kitch; Raymond T Chung; Colleen Hadigan; Janet Andersen; Phyllis Tien; Annie Luetkemeyer; Beverly Alston-Smith; Marshall J Glesby
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

5.  Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey.

Authors:  Ajit Sood; Shiv Kumar Sarin; Vandana Midha; Syed Hissar; Neena Sood; Pankaj Bansal; Manu Bansal
Journal:  Indian J Gastroenterol       Date:  2012-10-17

6.  The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population.

Authors:  J E Forrester; B H McGovern; M S Rhee; R K Sterling
Journal:  HIV Med       Date:  2009-06-01       Impact factor: 3.180

Review 7.  Women and HIV infection: the makings of a midlife crisis.

Authors:  Nanette Santoro; Maria Fan; BatSheva Maslow; Ellie Schoenbaum
Journal:  Maturitas       Date:  2009-09-23       Impact factor: 4.342

8.  Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus.

Authors:  C Castaneda-Sceppa; O I Bermudez; C Wanke; J E Forrester
Journal:  J Viral Hepat       Date:  2008-12       Impact factor: 3.728

9.  Altered or Impaired Immune Response to Hepatitis B Vaccine in WNIN/GR-Ob Rat: An Obese Rat Model with Impaired Glucose Tolerance.

Authors:  Prathibha Bandaru; Hemalatha Rajkumar; Giridharan Nappanveettil
Journal:  ISRN Endocrinol       Date:  2011-08-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.